NCT02172326已完成3 期
The Pharmacokinetics, Safety and Tolerability of Tiotropium in Elderly COPD Patients (Open Label, Monocenter Study).
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 29
- 主要终点
- Total area under the plasma drug concentration-time curve (AUC 0-4 h)
研究概览
简要总结
Study to evaluate the pharmacokinetics of tiotropium following 14 days of administration (18µg once per day) in elderly COPD patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients were required to have a diagnosis of COPD and to meet the following spirometric criteria:
- •Relatively stable, moderate to severe airway obstruction with an FEV1 ≤ 65% of predicted normal and FEV1/FVC ≤ 70%
- •Patients were required to have normal renal clearance. Renal clearance will be evaluated by the determination of creatinine clearance. To qualify for this trial, the patient's measured creatinine clearance was required to be within 20% of the calculated creatinine clearance, as given by the following equations:
- •Males: Calculated Creatinine Clearance (ml/min) = [140 - Age (yrs)] x weight(kg) / 72 x serum creatinine (mg/dL)
- •Females: Calculated Creatinine Clearance (ml/min) = [140 - Age (yrs)] x weight (kg) / 85 x serum creatinine (mg/dL)
- •Both male or female patients were eligible. Twelve patients ≥ 70 years old and twelve patients ≤ 50 years
- •Patients were required to have a smoking history of more than ten pack-years, where a pack-year was defined as the equivalent of smoking one pack of cigarettes per day for a year
- •Patients must be able to perform all specified procedures and maintain records during the study period as required in the protocol
- •Patients were required to be able to inhale medication from the HandiHaler®
- •Patients were required to sign an Informed Consent Form prior to participation in the trial, including any necessary prior to pre-study washout of their usual pulmonary medications
排除标准
- •Patients with significant diseases other than COPD were excluded from participation in the trial. A significant disease was defined as a disease which in the opinion of the investigator may either have put the patient at risk because of participation in the trial or a disease which may have influenced the results of the trial or the patient's ability to participate in the trial;
- •Patients with clinically significant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defined a disease listed as an exclusion criterion;
- •Patients with alanine transaminase (ALT/SGOT) > 80 IU/L or aspartate transaminase (AST/SGPT) > 80 IU/L, or bilirubin > 2.0 mg/dL or creatinine > 2.0 mg/dL were excluded from participation in the trial, regardless of the patient's clinical condition. Repeat laboratory evaluations were not conducted in these patients;
- •Patients with a recent history (i.e., one year or less) of myocardial infarction (MI);
- •Patients with a recent history (i.e., three years or less) of heart failure or patients with any cardiac arrhythmia requiring drug therapy;
- •Patients with regular use of daytime oxygen therapy;
- •Patients with known active tuberculosis;
- •Patients with a history of cancer within the last five years. However, patients with treated basal cell carcinoma are allowed to participate;
- •Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis;
- •Patients who had undergone thoracotomy with pulmonary resection. Patients with a history of a thoracotomy for other reasons were evaluated as per exclusion criterion # 1;
- •Patients who had developed an upper respiratory tract infection in six weeks prior to the Screening Visit (Visit 1) or during the baseline period;
- •Patients with known hypersensitivity to anticholinergic drugs, lactose or any other components of the inhalation capsule delivery system;
- •Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction;
- •Patients with known narrow-angle glaucoma;
- •Patients treated with cromolyn sodium or nedocromil sodium;
- •Patients treated with antihistamines (H1 receptor antagonists);
- •Patients using oral corticosteroid medication at unstable doses (i.e. less than six weeks on a stable dose) or at a dose in excess of the equivalent of 10 mg of prednisone per day (or 20 mg every other day);
- •Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm or Norplant®);
- •Patients with a history of asthma, allergic rhinitis or atopy or patients with a total blood eosinophil count ≥ 600/mm
- •A repeat eosinophil count was not conducted in these patients;
- •Patients with history and/or active alcohol or drug abuse.
- •Patients who had taken an investigational drug within one month or six half lives (whichever was greater) prior to Screening Visit (Visit 1).
研究组 & 干预措施
Tiotropium inhalation capsules
Experimental
干预措施: Tiotropium inhalation capsules for oral inhalation (Drug)
结局指标
主要结局
Total area under the plasma drug concentration-time curve (AUC 0-4 h)
时间窗: pre-dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14
Urinary excretion of tiotropium (Ae(0-4 hours))
时间窗: screening and on days 1, 7, 14, 15, 16, 20, 24, 28, 31, 35, 38
Renal clearance of tiotropium (CLren)
时间窗: screening and on days 1, 7, 14, 15, 16, 20, 24, 28, 31, 35, 38
Terminal elimination half-life after the last dose
时间窗: pre dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14
次要结局
- Changes form baseline in vital signs (pulse rate and blood pressure)(up to day 38)
- Changes from baseline in laboratory tests (haematology, clinical chemistry and urinalysis)(baseline, day 38)
- Changes from baseline in physical examination(baseline, day 38)
- Changes from baseline in ECG (Electrocardiogram)(baseline, day 1, 7, 14 and 38)
- Change from baseline in FEV1 (Forced expiratory volume in one second)(Baseline, Days 1, 7 and 14)
- Change from baseline in FVC (Forced vital capacity)(Baseline, Days 1, 7 and 14)
- FEV1/FVC(Baseline, Days 1, 7 and 14)
- Symptom evaluation(2 weeks)
- Use of salbutamol(2 weeks)
- Occurrence of Adverse Events(up to day 38)
- Plasma concentration of drug 5 min after inhalation (C5min)(pre dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14)
- tmax (time of occurrence for maximum drug concentration)(pre dose and 5, 20 min., 1, 2,and 4 hours after dosing on days 1, 7 and 14)
研究者
相似试验
已完成
1 期
The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy SubjectsRenal InsufficiencyNCT02172339Boehringer Ingelheim24
已完成
1 期
To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)COPDNCT01785433Teva Branded Pharmaceutical Products R&D, Inc.36
进行中（未招募）
不适用
Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)EUCTR2009-016251-21-DKBoehringer Ingelheim (UK) Ltd160
进行中（未招募）
不适用
Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-016251-21-FIBoehringer Ingelheim Finland Ky160
进行中（未招募）
不适用
Pharmacokinetics and dose-ranging of tiotropium inhalation solution delivered from the Respimat inhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-016251-21-NLBoehringer Ingelheim160